Group B Streptococcus Infection Treatment Market: Overview
- Group B streptococcus (GBS) infection, also known as group B strep infection, is a type of bacterial infection that can be found in the digestive and lower reproductive tracts of both men and women. About 1 in 4 pregnant women carries or is colonized with group B streptococcus. As per the WHO, group B streptococcus infection causes an estimated 150,000 preventable still births and infant deaths every year. Around 21.7 million pregnant women carry this bacteria, according to the first global study of group B strep. Most of them are currently unidentified and untreated. An estimated 1 in 5 pregnant women around the world carries the group B streptococcus bacteria, which is a major yet preventable cause of maternal and infant ill-health globally.
Read Report Overview: https://www.transparencymarketresearch.com/group-b-streptococcus-gbs-infection-treatment-market.html
Key Drivers, Restrains, and Opportunities of Global Group B Streptococcus Infection Treatment Market
- There are three types of perinatal group B streptococcus diseases, each with their own prevention challenges. They are prenatal-onset GBS disease (before birth), early-onset GBS disease (birth through the first week of life), and late-onset GBS disease (over one week of age through several months of age). A study by the London School of Hygiene and Tropical Medicine estimated that out of 410,000 group B streptococcus cases every year, at least 147,000 stillbirths and infant deaths are estimated to occur globally. Africa had the highest burden, with 54% of estimated cases and 65% of stillbirths and infant deaths. A rise in the prevalence of group B streptococcus infections and the rate of new infections is likely to drive the global group b streptococcus infection treatment market. Furthermore, an increase in modes of transmission of the infectious disease and lack of cleanliness in developing regions are estimated to propel the group B streptococcus infection treatment market in the region.
Request a Sample of Group B Streptococcus Infection Treatment Market: https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=64904
Global Group B Streptococcus Infection Treatment Market: Segmentation
- The global group B streptococcus infection treatment market can be segmented based on GBS type, route of administration, drug molecule, distribution channel, and region. In terms of type of GBS type, the global market can be categorized into prenatal-onset GBS disease, early-onset GBS disease, and late-onset GBS disease. Based on route of administration, the global group B streptococcus infection treatment market can be bifurcated into oral and parenteral. In terms of drug molecule, the global group B streptococcus infection treatment market can be divided into small molecule, vaccines, and others. Current group B streptococcus prevention focuses on administering antibiotics to women in labor, with an aim to reduce the disease in infants at delivery. Several vaccines to prevent group B streptococcus are in development; however, none is currently available. Based on distribution channel, the global group B streptococcus infection treatment market can be classified into hospital pharmacies, retail pharmacies, and online pharmacies. The retail pharmacies segment accounted for a considerable share of the group B streptococcus infection treatment market due to the availability of generic drugs.
Enquiry before Buying Group B Streptococcus Infection Treatment Market Report – https://www.transparencymarketresearch.com/sample/sample.php?flag=EB&rep_id=64904
Global Group B Streptococcus Infection Treatment Market: Regional Analysis
- In terms of region, the global group B streptococcus infection treatment market can be segmented into North America (U.S. and Canada), Europe (U.K., Germany, France, Italy, Spain, and Rest of Europe), Asia Pacific (Japan, India, China, Australia & New Zealand, and Rest of Asia Pacific), Latin America (Mexico, Brazil, and Rest of Latin America), and Middle East & Africa (Saudi Arabia, South Africa, Israel, and Rest of Middle East and Africa). Prevalence of group B streptococcus infection is higher in Asia Pacific and Middle East & Africa as compared to that in North America and Europe. According to statistics published by the World Health Organization in 2017, the top five countries by numbers (to nearest 100) of pregnant women colonized were: India (2,466,500), China (1,934,900), Nigeria (1,060,000), the U.S. (942,800), and Indonesia (799,100). However, in the U.S., it is recommended that women be screened for group B streptococcus during weeks 35 to 37 of pregnancy. Pregnant women testing positive are administered an intravenous antibiotic before delivery to prevent group B streptococcus, which could manifest shortly after birth (early onset disease). In developing countries, the infrastructure to provide screening and preventative antibiotics is either nonexistent or limited, resulting in much higher observed group B streptococcus disease burden in babies.
Pre-book Group B Streptococcus Infection Treatment Market Report – https://www.transparencymarketresearch.com/checkout.php?rep_id=64904<ype=S
Key Players Operating in Global Group B Streptococcus Infection Treatment Market
Key players developing therapeutics for group B streptococcus infections are Pfizer Inc., Alopexx Pharmaceuticals, LLC, Wellstat Vaccines LLC, Minervax ApS, Novartis, GlaxoSmithKline, and other prominent players. In 2017, Pfizer started phase I/II trial of its group B streptococcus conjugate vaccine named PF-06760805, which incorporates at least five serotypes of group B streptococcus and could prevent approximately 95% of group B streptococcus disease in infants via maternal immunization.
More Trending Reports by Transparency Market Research:
About Us
Transparency Market Research is a global market intelligence company providing global business information reports and services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insight for thousands of decision makers. Our experienced team of analysts, researchers, and consultants use proprietary data sources and various tools and techniques to gather and analyze information.
Our data repository is continuously updated and revised by a team of research experts, so that it always reflects the latest trends and information. With a broad research and analysis capability, Transparency Market Research employs rigorous primary and secondary research techniques in developing distinctive data sets and research material for business reports.
Contact
Transparency Market Research,
90 Sate Street, Suite 700,
Albany, NY 12207
Tel: +1-518-618-1030
USA – Canada Toll Free: 866-552-3453
Website: https://www.transparencymarketresearch.com/
